Compare Essex Property Trust, Inc. (ESS) vs Summit Therapeutics Inc (SMMT) Price & Performance

ESS trades at $271.57, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 results beating FFO guidance and raised full-year outlook, while resolving major litigation. Fundamentals show solid revenue growth to $1.89B in 2025 with 21.48% net margins, though valuation multiples remain elevated with P/E of 41.83.

Outlook remains cautiously optimistic with analyst consensus target of $303.41 offering 12% upside potential. Key opportunities include sustained West Coast multifamily demand and operational efficiency, while risks involve elevated debt levels and potential regional economic headwinds affecting rental markets.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.